At Welab, we believe that partnership
in biomedical innovation has the potential to bring innovative treatments to patients
is the World Leader in Drug Discovery and Development targeting Sigma receptors.
We aim to create the next generation of disease modifying therapies to reverse CNS diseases and neuronal loss.
We are a patient centric company focused on drug innovation and
partnered development, with a strong pipeline of oral medicines, created with
world class chemistry and exclusively targeting diseases of the CNS, with optimized receptor pharmacology and a truly differentiated
understanding of the neurocircuitry.